Objective -To assess the association between cardiovascular risk factors and acute myocardial infarction as the first manifestation of ischemic heart disease, correlating them with coronary angiographic findings.
Ischemic heart disease continues to be one of the major causes of death in industrialized countries, atherosclerosis being its etiopathogenic substrate 1 . Several factors related to the severity of the disease were identified as follows: systemic arterial hypertension, smoking, age, sex, diabetes mellitus, the number of arteries impaired, and degree of functional impairment of the left ventricle 2 . According to the literature, acute myocardial infarction is the first manifestation of ischemic heart disease in approximately 50% to 70% of patients [3] [4] [5] [6] . It has not yet been established whether any of the risk factors has an independent participation in the instability of the plaque for triggering myocardial infarction as the first manifestation of ischemic heart disease 7 . Acute myocardial infarction with no previous angina has been suggested to be more prevalent in young males, and to relate to impairment of a single vessel and a better clinical evolution [8] [9] [10] . Other studies disagree about the importance of these risk factors 10 . Therefore, a controversy persists in regard to several conditions that characterize patients with acute myocardial infarction as the first manifestation of ischemic heart disease.
The objective of this study was to delineate the incidence of acute myocardial infarction as the first manifestation of ischemic heart disease and to investigate the participation of risk factors in patients who experience myocardial infarction as the first manifestation of disease, as compared with other patients with angina preceding myocardial infarction. We also aimed at assessing, from the angiographic point of view, whether a difference in the degree of obstruction exists.
Methods
We carried out a cross-sectional study of 104 patients with acute myocardial infarction confirmed by clinical, electrocardiographic, and enzymatic methods, who were admitted to the Hemodynamics Unit of the Cardiology Service of the Hospital de Clínicas de Porto Alegre (HCPA), with an indication for undergoing coronary angiography. Through application of a standard questionnaire, we obtained data on risk factors for ischemic heart disease, such as systemic arterial hypertension, smoking, obesity, diabetes mellitus, sex, and familial history. Presence or absence of symptoms preceding acute myocardial infarction, such as pain or other equivalent symptoms (arrhythmias, dizziness, fatigue, or dyspnea on exertion) were also assessed through the questionnaire. If pain were present, the following topics were approached: beginning, location, intensity, characteristics (grasp, twinge, burning sensation); irradiation (arms, shoulders, neck, mandible, posterior cervical region, dorsum, ulnar region, and epigastric region); relief conditions (rest, nitrate, ingestion of liquids, changes in position); worsening and triggering conditions (exertion, emotions); and duration of the pain (seconds, 1 to 5 minutes, 5 to 10 minutes, 10 to 20 minutes, and more than 20 minutes). These data were related to the severity and extensiveness of the coronary heart disease, in addition to the presence of collateral circulation, determined through coronary angiography. Hemodynamic and cineangiocardiographic studies were performed with left cardiac catheterization with dissection of the right brachial artery or puncture through the right femoral artery with the patient under local anesthesia (2% lidocaine). Selective coronary angiography was performed according to the technique of Sones and Sinrey 10 , and Judikins 11 . Cineangiocardiographic films were interpreted by 2 experienced researchers, who ignored the presence or absence of risk factors, and of a previous history of acute myocardial infarction. Hypertrophy was defined using cineventriculographic findings of ventricular wall thickness and echocardiographic findings. To quantify the severity of coronary artery stenoses, we used the degrees of stenosis as follows 12 : <50%, severity=0; from 50% to 74%, severity=1; from 75% to 90%, severity=2; and >90%, severity=3.
Before undergoing the procedure, the patients were invited to participate in the study and to sign a written informed consent approved by the Committee on Ethics of the Research and Postgraduate Group of the HCPA, authorizing the withdrawal of 10 mL of blood for later serum lipid analysis. The blood sample collected underwent the following analyses in the Biochemistry Unit of the HCPA: total cholesterol and triglycerides (colorimetric enzymatic method using the Autoanalyser Selectra-Vitaldo, Merck), HDL-C and LDL-C (selective ionic precipitation /colorimetric enzymatic method).
The patients were considered hypertensive when they reported a history of hypertension diagnosed in a medical service where they were treated and when they were on dietary or pharmacological treatment, or both. Smoking was defined as the consumption of at least 5 cigarettes per day for at least 1 year over the last 5 years. The diabetic patients were those with a confirmed diagnosis of diabetes mellitus. Obesity was defined by the Quetelet index, according to the National Institutes of Health Consensus Development 13 . In females, a Quetelet index >27.3 was considered obesity, which in males occurred for values >27.8. The limits considered normal in the samples studied were the following: total cholesterol <200 mg/dL, HDL cholesterol >40mg/dL, LDL cholesterol <130mg/dL. The cut points for triglycerides were <140mg/dL for patients 30 years or younger, <150mg/dL for patients from 31 to 40 years, <160mg/dL for patients from 41 to 50 years, and <160mg/dL for patients older than 50 years (according to the standards of the kit used for analysis).
To assess the association between potential risk factors and manifestation of ischemic heart disease, the chisquare test was used with continuity correction (Yates), except for severity (Pearson chi-square) and race (Fischer exact test), in addition to the prevalence rate (relative risk) and 95% confidence interval. To control confounding and interaction factors, multiple logistic regression was used. The significance level used was 0.05 (P<0.05). The version 6.0 of the SPSS program was used.
Results
Of the 104 patients studied, 51 (49%) had acute myocardial infarction as the first manifestation of ischemic heart disease.
Of the nonhypertensive patients, 64.6% developed acute myocardial infarction as the first manifestation as compared with 35.4% of the hypertensive patients (RR= 0.55; 95% CI= 0.36-0.83). The remaining risk factors did not show statistical significance for the development of acute myocardial infarction as the first manifestation of ischemic heart disease (table I) .
In multivariate analysis, the greater prevalence of acute myocardial infarction as the first manifestation of ischemic heart disease in nonhypertensive patients remained statistically significant (RR=0.19; 95% CI=0.06-0.6). The presence of acute myocardial infarction as the first manifestation was less prevalent among patients with myocardial hypertrophy (RR=0.27; 95% CI=0.08-0.88). The remaining factors included in the multivariate analysis, such as diabetes mellitus, smoking, familial history of ischemic heart disease, age, the total cholesterol/HDL ratio, and coronary artery stenosis were not statistically significant (table II) . 
Discussion
Better understanding of the pathophysiology of the clinical events of coronary atherosclerosis, recognition of the efficacy of primary and secondary preventive measures, and the introduction of new therapeutic managements have changed the evolution profile of ischemic heart disease.
In our study, prevalence of acute myocardial infarction as the first manifestation of ischemic heart disease was 49%; the remaining 51% corresponded to chronic angina. In the literature, prevalence of chronic angina prior to infarction ranges from 25% to 50% [14] [15] [16] . These differences may be attributed to diverse definitions of chronic angina and different populations studied.
Bechar et al 6 reported the presence of angina prior to acute myocardial infarction in 43% of patients, in accordance with our study, in which angina prior to infarction was more common among hypertensive patients. However, the authors found a higher prevalence in females and diabetic patients. In addition, angina prior to acute myocardial infarction was a risk factor for higher in-hospital mortality and mortality 5 years after hospital discharge.
Our results showed that, except for hypertension, the remaining factors studied had no statistical significance in regard to ischemic heart disease presentation, even though the findings in the literature do not agree about this topic.
A cohort study 6 conducted with 732 patients admitted to the hospital due to first acute myocardial infarction showed that 39% of the patients had no previous angina. Patients with previous angina were older, mainly females, and most frequently the previous acute myocardial infarction and postinfarction angina were early, being statistically significant. In-hospital mortality was similar in both groups, but in the 3 years following hospital discharge, it was higher in patients with previous angina (16% versus 7%). Another cohort study 15 , carried out with 587 patients, reported a 52% incidence of angina prior to infarction (in the preceding month). The study divided the patients into 4 groups as follows: no angina prior to acute myocardial infarction, chronic unstable angina, chronic stable angina, and angina of recent onset. No significant difference in sex and age was observed in the groups. Patients with chronic angina were more susceptible to developing infarction than patients with no previous angina (50% versus 14%). In-hospital mortality did not differ in the groups 15 . Our study showed a greater incidence of ventricular hypertrophy in patients with previous angina. Therefore, we can conclude that the greater oxygen consumption by the ventricular mass was not satisfied because of the coronary artery obstruction, which caused the anginal symptoms.
In a study by Matsuda et al 9 , where the ventricular function of 31 patients with total occlusion of the anterior descending coronary artery and stenosis <70% in any other coronary artery was assessed, 16 patients had no history of previous angina. Patients with angina prior to acute myocardial infarction showed better ejection fraction, a lower percentage of abnormalities in contractile segments and in regional motility of the cardiac wall, suggesting that previous angina contributes to preservation of postinfarction ventricular function 7 . Kobayashi et al 17 , however, reported that a worse long-term prognosis is associated with multiple-vessel coronary heart disease in patients with angina prior to infarction.
In conclusion, based on the findings of the present study, 49% of patients experiencing acute myocardial infarction do not have previous manifestations of coronary artery disease. This figure is close to those obtained in other studies, and it makes the clinical history of previous angina of little value for these groups. Patients with left ventricular hypertrophy and systemic arterial hypertension most frequently have angina prior to acute myocardial infarction; the other risk factors showed no participation in the acute myocardial infarction event with or without previous manifestations. This may result from the disparity between metabolic offer and demand in the presence of greater afterload. 
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